Up 40%: Is This Red-Hot Growth Stock Still a Buy?
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
Agenus Announces Reverse Stock Split of Common Stock
Agenus Reports Fourth Quarter and Full Year 2023 Results
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Agenus to Provide Update and Fourth Quarter & Full Year 2023 Financial Report
Agenus to Participate in Leerink Partners Global Biopharma Conference